Skip to content

Allen & Overy advises on Immunotech Biopharm’s global offering and listing on the Hong Kong Stock Exchange

Related people
Lee Lina
Lina Lee

Partner

Hong Kong

View profile →

Liu Kung-Wei
Kung-Wei Liu

Partner

Hong Kong

View profile →

Press contacts

For media enquiries relating to this topic, please contact:

Mirpuri Madhu
Madhu Mirpuri

Marketing and Communications Manager

Hong Kong

View profile →

10 July 2020

Allen & Overy has advised the joint sponsors on the global offering and listing of shares of Immunotech Biopharm Ltd (Immunotech Biopharm) on the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules for pre-revenue biotech companies.

Immunotech Biopharm is a cancer immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T-cell immunotherapy for over 13 years.

CCB International Capital Limited and Guosen Securities (HK) Capital Company Limited acted as the joint sponsors. CCB International Capital Limited, Guosen Securities (HK) Capital Company Limited and Haitong International Securities Company Limited acted as the joint global coordinators.

The Allen & Overy team comprises Corporate partner Lina Lee, International Capital Markets partner Kung-Wei Liu, and other members including Zoe Guan, Arthur Wong, Shue Sing Churk, Veronica Tse, Xunming Lim, Martin Hui and Curtis Fung. Zhen Gu from Allen & Overy Lang Yue (FTZ) Joint Operation Office also contributed. The joint operation brings together Lang Yue’s high-quality execution capability and Allen & Overy’s international platform, to provide clients with seamless PRC and international legal services across a wide range of capabilities.